These results highlight that signaling through NKG2D (KLRK1), NKp44 (NCR2), and CD160 receptors may be critical in the downstream activation of tumour infiltrating CD56bright NK and/or CD8+ TEM cells, which may contribute to a more favourable BLCA prognosis. The gene discussed is NCR2; the disease is neoplasm.